Welcome to our dedicated page for Aim Immunotech SEC filings (Ticker: AIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AIM ImmunoTech Inc. (AIM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include annual reports on Form 10‑K, quarterly reports on Form 10‑Q, current reports on Form 8‑K, registration statements such as Form S‑1 and S‑1/A, proxy statements on Schedule 14A, and notifications of late filing on Form 12b‑25.
Through its filings, AIM ImmunoTech describes its business as an immuno-pharma company focused on research and development of therapeutics for cancers, viral diseases, and immune-deficiency disorders, with flagship products Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa. Registration statements and prospectuses detail capital-raising transactions, including offerings of common stock, pre‑funded warrants, Class E and Class F warrants, and rights offerings involving Series G Convertible Preferred Stock and warrants. These documents outline terms such as subscription rights, exercise prices, and use of proceeds.
Current reports on Form 8‑K capture material events, such as entry into a Note Purchase Agreement for an unsecured promissory note with an institutional investor, the closing of public offerings, the filing of corporate charter documents, and the release of corporate presentations. Filings also describe exchange listing matters, including temporary suspension of trading on the NYSE American, trading on the OTC Pink under a different symbol, and subsequent reinstatement on the NYSE American under the AIM symbol.
Investors can review notifications of late filing, such as Form 12b‑25, which explain delays in filing periodic reports and provide preliminary estimates of changes in revenues and net loss. Definitive proxy statements (DEF 14A) provide information on director elections, advisory votes on executive compensation, auditor ratification, and the company’s status as a smaller reporting company.
On Stock Titan, AIM ImmunoTech’s filings are updated as new documents are released on EDGAR. AI-powered summaries help explain the key points of lengthy filings, including risk factor discussions, financing structures, and governance proposals, so that readers can more quickly understand what each 10‑K, 10‑Q, 8‑K, or registration statement means for the company.
AIM ImmunoTech Inc. CEO and President Thomas K. Equels converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock. The preferred stock position was reduced to zero, and his directly held common stock increased to 63,922 shares following the transaction.
AIM ImmunoTech Inc. director David I. Chemerow converted preferred stock into common shares. He converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock through a derivative conversion at no stated cash price. A footnote explains each preferred share is convertible into 1,000 common shares, effectively valuing the conversion at $1.00 per common share. Following the conversion, he directly holds 28,441 shares of AIM ImmunoTech common stock, with no remaining Series G preferred shares reported.
AIM ImmunoTech Inc. CEO and President Thomas K. Equels reported changes in his holdings of derivative securities related to a rights offering. On March 6, 2026, he held 25 shares of Series G Convertible Preferred Stock, each with a stated value of
AIM ImmunoTech director David I. Chemerow reported new derivative holdings tied to a rights offering. He now holds 25 shares of Series G Convertible Preferred Stock, each with a stated value of
He also reported 50,000 Class G Warrants, each exercisable for one share of common stock at an exercise price of
AIM ImmunoTech Inc. completed a previously announced rights offering, raising approximately $1.8 million by selling 1,842 units. Each unit included one share of Series G Convertible Preferred Stock and Class G warrants.
The company created a new Series G preferred series of 12,000 shares, each with a stated value of $1,000 and initially convertible into common stock at $1.00 per share, subject to standard anti-dilution adjustments. Conversions are limited so that holders generally cannot exceed 4.99% beneficial ownership, adjustable by the holder up to 9.99%. The rights offering also issued 3,684,000 Class G warrants, each exercisable for one share of common stock at $1.00 per share for five years. The Series G preferred is non-voting (with limited exceptions), participates with common stock in dividends and liquidation on an as-converted basis, and has no mandatory redemption features.
AIM ImmunoTech Inc. is offering Subscription Rights to purchase up to 12,000 Units. Each Unit carries one share of Series G Convertible Preferred Stock (convertible at a $1.00 conversion price) and 2,000 Warrants exercisable at $1.00 per share, representing up to 24,000,000 Warrant shares and up to 12,000,000 common shares issuable on conversion.
The Rights Offering has a subscription price of $1,000 per Unit, a Record Date of February 10, 2026, and an expiration date of March 3, 2026. The supplement revises earlier terms by lowering the conversion and exercise prices to $1.00 and increasing the number of Warrants to 24,000,000.
ImmunoTech Inc. is conducting a rights offering of up to 12,000 Units at $1,000 per Unit, for up to $12 million in gross proceeds. Each Unit includes one share of Series G convertible preferred stock plus 1,666 five-year warrants, each warrant exercisable at $1.20 per share.
Each preferred share is convertible into common stock at $1.20 per share, so a fully subscribed offering would add up to 9,996,000 shares from conversions and 19,992,000 shares from warrant exercises. Existing common and specified warrant and option holders receive one non‑transferable subscription right per share as of February 10, 2026, with rights expiring on February 27, 2026.
The company expects net proceeds of about $10.65 million if fully subscribed, before other expenses and excluding any warrant exercise proceeds, and plans to use the cash for general corporate purposes, including clinical trial and manufacturing costs for pancreatic cancer programs, and to repay certain debt.
ImmunoTech Inc. filed Amendment No. 3 to its Form S-1 registration statement as an exhibits-only update, amending Item 16(a) in Part II while leaving the remainder of the registration statement unchanged.
The amendment provides a detailed estimate of issuance and distribution expenses totaling $272,262, including an SEC registration fee of $4,971.60, a FINRA filing fee of $5,900.00, and legal, accounting, agent and miscellaneous fees. It also restates Delaware law-based indemnification provisions for directors and officers, summarizes prior unregistered securities issuances to executives and directors under Section 4(a)(2) and Rule 701, lists extensive material contracts and corporate documents as exhibits, and includes standard Securities Act undertakings and signature blocks.
ImmunoTech Inc. director David I. Chemerow reported an indirect acquisition of common stock through The David I Chemerow 1992 Trust. On 02/05/2026, the trust acquired 2,800 shares of ImmunoTech common stock at a price of $1.23 per share.
Following this transaction, the trust beneficially owned a total of 3,441 ImmunoTech common shares, all reported as indirectly held on behalf of Chemerow.